Natural History of a Patient with Sacral Chordoma: Case Report and Literature Review

Kennamer, Brooke; Gridley, Daniel; Rhines, Laurence D.; Nair, Geetha R.; Lettieri, Salvatore C.; Davis, Karole M.; Feiz-Erfan, Iman

doi:10.1016/j.wneu.2020.03.214

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This approach, done predominantly with the CyberKnife SRS/SBRT system and in combination with surgery on a neoadjuvant or adjuvant basis, has been explored in several studies [8][9][10][11] with 2-year local control rates varying from 75 to 96%. For patients managed with palliative intent due to personal choice or underlying competing comorbidities, the presence of an untreated sacral chordoma may not necessarily reduce overall survival, even with negative prognostic factors such as advanced patient age, high sacral location, and large tumour size [12]. However, such patients may face significant symptoms including chronic pain, difficulty with ambulation, sexual dysfunction, and bowel and urinary issues, affecting quality of life and causing caregiver distress [13].…”

Section: Discussionmentioning

confidence: 99%

Treatment Response of Sacrococcygeal Chordoma to Palliative Stereotactic Body Radiotherapy: A Case Report

Ho¹,

Nei²

2023

Case Rep Oncol

View full text Add to dashboard Cite

Chordomas are rare and locally aggressive tumours that arise from embryonic remnants of the notochord, with a predilection for the skull base, mobile spine, and sacrum. Sacral or sacrococcygeal chordomas can be particularly difficult to manage because of their large size at presentation and involvement of adjacent organs and neural structures. Although the recommended definitive therapy for such tumours is either en bloc resection with or without adjuvant radiotherapy (RT) or definitive fractionated RT with charged particle therapy, older and/or less-fit patients may not necessarily be accepting of said approaches due to the potential morbidities and challenging logistic requirements. Here, we report a case of a 79-year-old male presenting with intractable lower limb pain and neurologic deficits due to a large de novo sacrococcygeal chordoma. The patient was successfully treated with a 5-fraction course of stereotactic body radiotherapy (SBRT), given with palliative intent, with complete relief of his symptoms achieved approximately 21 months after RT and without the development of any iatrogenic toxicities. In view of this case, ultra-hypofractionated SBRT may be a suitable option for the palliation of large de novo sacrococcygeal chordomas for selected patients to reduce their symptom burden and improve their quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment Response of Sacrococcygeal Chordoma to Palliative Stereotactic Body Radiotherapy: A Case Report

Ho¹,

Nei²

2023

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…In the combined anterior and posterior approach, many complications such as long operation time, a large amount of bleeding, wound dehiscence, and infection has been reported 1,6) . The posterior only approach was first reported in 1987 7) . Although the posterior-only approach has the disadvantage in dissection of visceral organs and preservation of sacral nerve roots, it has shown favorable results compared to the anterior approach 5) .…”

Section: Discussionmentioning

confidence: 99%

The Single Posterior Approach for Resection of Sacral Chordoma: A Case Report

Mun

Kim²,

Hyun

et al. 2022

Nerve

View full text Add to dashboard Cite

Chordoma is a primary malignant neoplasm that is a slow-growing and locally aggressive tumor 3) . Although it is relatively rare, chordoma is the most frequent primary malignant tumor in the sacrum. It is found in men more than in women (2:1) 11) . The sacral chordoma is often large at the time of diagnosis because of its minimal symptoms and deeply seated location.The first line of treatment is surgical resection rather thanChordoma is a relatively rare primary malignant neoplasm that originates from ectopic notochordal cells, and most chordomas arise in the sacrococcygeal and clivus regions. Due to the poor response to adjuvant therapy, complete tumor resection is the treatment of choice. This case report describes a 57-year-old male patient who presented with a very large sacral chordoma involving the S2-S5 bodies, extending to the right piriformis and gluteal muscles. He was successfully treated with a single-stage posterior approach and was free of local recurrence at a 5-year follow-up examination, without neurological deficits. A single posterior approach is a feasible option for the treatment of sacral chordomas.

show abstract

“…Tumores de células gigantes e plasmocitomas também podem apresentar semelhanças radiológicas com os CS. Além disso, não é incomum a ocorrência de lesões metastáticas no sacro derivadas de tumores na próstata, mama, tireoide, pulmões e cólon, especialmente em idosos 2,3,5 .…”

Section: Relato De Casounclassified

Cordoma sacral metastático

Costa

Visgueira

Neto³

et al. 2022

Medicina (Ribeirão Preto)

View full text Add to dashboard Cite

Os cordomas sacrais (CS) são tumores ósseos malignos primários da coluna vertebral de ocorrência rara, com incidência entre 0,000005-0,000027%. O objetivo deste estudo é relatar um caso de CS metastático. Homem de 41 anos de idade, sem comorbidades, chega ao serviço de referência apresentando lesão sacral. Ressonância magnética mostrou tratar-se de tumor com 9,3 cm sugestivo de mieloma ou cordoma. Realizou-se biópsia e histopatológico, confirmando o diagnóstico de CS. O paciente submeteu-se à excisão cirúrgica do tumor. 6 meses após a cirurgia, este evoluiu com recidiva e implantes metastáticos em coluna vertebral, partes moles da parede torácica, fígado e espaço pleural, evoluindo com paraplegia. Não havia indicação de radioterapia e/ou quimioterapia adjuvante. Não havia também possibilidade de liberação de imatinibe pelo Sistema Único de Saúde. Em cerca de 28 meses de seguimento clínico mensal, o paciente foi a óbito. O caso apresentado mostrou um CS sem sucesso cirúrgico, o que é associado a pior prognóstico. O paciente apresentou disseminação sistêmica do tumor e paraplegia poucos meses após a cirurgia, indo a óbito em 28 meses de seguimento.

show abstract

Natural History of a Patient with Sacral Chordoma: Case Report and Literature Review

Cited by 4 publications

References 17 publications

Treatment Response of Sacrococcygeal Chordoma to Palliative Stereotactic Body Radiotherapy: A Case Report

Treatment Response of Sacrococcygeal Chordoma to Palliative Stereotactic Body Radiotherapy: A Case Report

The Single Posterior Approach for Resection of Sacral Chordoma: A Case Report

Cordoma sacral metastático

Contact Info

Product

Resources

About